Clovis Oncology (NASDAQ:CLVS) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Clovis Oncology (NASDAQ:CLVSGet Rating) in a research note issued on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, JPMorgan Chase & Co. lowered Clovis Oncology from a “neutral” rating to an “underweight” rating in a research report on Wednesday, November 9th.

Clovis Oncology Stock Up 2.3 %

Shares of CLVS opened at $0.34 on Friday. The business’s 50 day moving average is $0.92 and its two-hundred day moving average is $1.21. Clovis Oncology has a 52-week low of $0.23 and a 52-week high of $3.41. The firm has a market cap of $49.29 million, a price-to-earnings ratio of -0.19 and a beta of 0.41.

Institutional Investors Weigh In On Clovis Oncology

A number of institutional investors have recently made changes to their positions in the company. State Street Corp increased its holdings in shares of Clovis Oncology by 18.5% in the 3rd quarter. State Street Corp now owns 715,398 shares of the biopharmaceutical company’s stock valued at $851,000 after acquiring an additional 111,500 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Clovis Oncology by 259.6% in the 3rd quarter. Marshall Wace LLP now owns 310,123 shares of the biopharmaceutical company’s stock valued at $370,000 after acquiring an additional 223,880 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Clovis Oncology by 39.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 97,995 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 27,477 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Clovis Oncology in the 3rd quarter valued at approximately $64,000. Finally, Barclays PLC increased its holdings in shares of Clovis Oncology by 245.7% in the 3rd quarter. Barclays PLC now owns 132,775 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 94,367 shares during the last quarter. 29.47% of the stock is currently owned by institutional investors.

About Clovis Oncology

(Get Rating)

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

See Also

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.